This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)

Tipranks - Tipranks - Wed Jun 10, 6:04AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM).

Introducing TipRanks MCP for Agents

Verastem (VSTM)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Verastem today and set a price target of $14.00. The company’s shares closed last Monday at $3.67, close to its 52-week low of $2.10.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 15.6% and a 42.2% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Verastem is a Strong Buy with an average price target of $16.00, which is a 319.9% upside from current levels. In a report issued on May 26, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

Jazz Pharmaceuticals (JAZZ)

In a report released yesterday, Jeffrey Walch from Bernstein reiterated a Hold rating on Jazz Pharmaceuticals, with a price target of $229.00. The company’s shares closed last Monday at $232.04.

According to TipRanks.com, Walch is a 2-star analyst with an average return of 12.0% and a 100.0% success rate. Walch covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Summit Therapeutics, and BioNTech SE. ;'>

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $259.08.

Humana (HUM)

In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Humana, with a price target of $425.00. The company’s shares closed last Monday at $355.98.

According to TipRanks.com, Wilkes is a 4-star analyst with an average return of 11.5% and a 64.2% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'>

Humana has an analyst consensus of Hold, with a price target consensus of $292.33, implying a -15.4% downside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $390.00 price target.

Read More on VSTM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).